Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5
Titel:
Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5
Auteur:
Parker, Maria A. Erker, Laura R. Audo, Isabelle Choi, Dongseok Mohand-Said, Saddek Sestakauskas, Kastytis Benoit, Patrick Appelqvist, Terence Krahmer, Melissa Ségaut-Prévost, Caroline Lujan, Brandon J. Faridi, Ambar Chegarnov, Elvira N. Steinkamp, Peter N. Ku, Cristy da Palma, Mariana Matioli Barale, Pierre-Olivier Ayelo-Scheer, Sarah Lauer, Andreas Stout, Tim Wilson, David J. Weleber, Richard G. Pennesi, Mark E. Sahel, José Alain Yang, Paul